Avalon GloboCare (NASDAQ:CHGA) and Figma (NYSE:FIG) Financial Survey

Avalon GloboCare (NASDAQ:CHGA) and Figma (NYSE:FIG) are both technology companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Avalon GloboCare and Figma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1	0	0	0	1.00
Figma	1	11	4	0	2.19

Figma has a consensus price target of $28.80, indicating a potential upside of 53.17%. Given Figma’s stronger consensus rating and higher possible upside, analysts clearly believe Figma is more favorable than Avalon GloboCare.

Institutional & Insider Ownership

1.4% of Avalon GloboCare shares are held by institutional investors. 16.8% of Avalon GloboCare shares are held by company insiders. Comparatively, 32.3% of Figma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Avalon GloboCare and Figma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-53.69%
Figma	-40.21%	-32.80%	-20.72%

Risk & Volatility

Avalon GloboCare has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500. Comparatively, Figma has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Earnings and Valuation

This table compares Avalon GloboCare and Figma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	N/A	N/A	-$18.26 million	($13.80)	-0.06
Figma	$1.40 billion	6.15	-$1.25 billion	($1.07)	-17.57

Avalon GloboCare has higher earnings, but lower revenue than Figma. Figma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Summary

Figma beats Avalon GloboCare on 8 of the 13 factors compared between the two stocks.

About Avalon GloboCare

Avalon GloboCare Corp. is a biotechnology company historically focused on developing cell-based technologies, regenerative medicine applications and precision-medicine solutions. Its work has included research and development involving cellular therapies, immunotherapy and other platforms intended to support the treatment of serious diseases. The company’s reported activities have included the development of CAR-T and other cell-therapy approaches, exosome-related technologies, and diagnostic and biobanking services.

About Figma

Figma, Inc. develops browser-based software for designing and building digital products. Its platform supports collaborative interface design, interactive prototyping and workflows that help teams plan, create and refine websites, apps and other digital experiences. Figma’s products include Figma Design for interface design and prototyping, FigJam for online whiteboarding and brainstorming, and Dev Mode, which helps developers inspect designs and access implementation details. Figma Slides provides tools for creating and presenting slide decks.